<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529853</url>
  </required_header>
  <id_info>
    <org_study_id>TDR11326</org_study_id>
    <secondary_id>2011-005481-37</secondary_id>
    <secondary_id>U1111-1124-1425</secondary_id>
    <nct_id>NCT01529853</nct_id>
  </id_info>
  <brief_title>To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Repeated Doses of SAR156597 in Patients With Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess in adult patients with Idiopathic Pulmonary Fibrosis (IPF) the safety and
      tolerability of ascending doses of SAR156597 administered subcutaneously (SC) once weekly
      over a 6-week period.

      Secondary Objectives:

      To assess in adult patients with IPF:

        -  The pharmacodynamic effects of SAR156597, as measured on pulmonary function tests
           (PFTs), pulse oximetry and patient reported outcome and peripheral blood biomarkers.

        -  The trough plasma concentrations of SAR156597

        -  The potential immunogenicity of SAR156597.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a screening period of up to 28 days, treatment period of up to 6 weeks
      and a post-treatment follow-up period of up to 12 weeks. Total study duration is up to 22
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/tolerability: Number of participants with Adverse events</measure>
    <time_frame>from first dose of study drug up to Week 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: Change in forced (expiratory) vital capacity (FVC)</measure>
    <time_frame>from baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: Change in carbon monoxide diffusing lung capacity (DLco)</measure>
    <time_frame>from baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: Change in Saint George Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>from baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: Change in plasma levels of biomarkers</measure>
    <time_frame>from baseline to week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: SAR156597 plasma concentration</measure>
    <time_frame>from baseline to week 18</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>SAR156597 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR156597 dose 1, subcutaneous injection once every week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR156597 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR156597 dose 2, subcutaneous injection once every week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR156597 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR156597 dose 3, subcutaneous injection once every week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for SAR156597), subcutaneous injection once every week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR156597</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>SAR156597 dose 1</arm_group_label>
    <arm_group_label>SAR156597 dose 2</arm_group_label>
    <arm_group_label>SAR156597 dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for SAR156597)</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Adult (aged &gt;18 years) male or female patients,

          -  Documented diagnosis of IPF according to the current American Thoracic
             Society/European Respiratory Society/Japanese Respiratory Society/American Latin
             Thoracic Association (ATS/ERS/JRS/ALTA) guidelines

        Exclusion criteria:

          -  Forced vital capacity (FVC) &lt;50% of predicted value Carbon monoxide diffusing lung
             capacity (DLCO) (corrected for hemoglobin) &lt;35% predicted value

          -  Oxygen saturation &lt;90% by pulse oximetry while breathing ambient air at rest (sitting
             position for 10 min)

          -  Known diagnosis of significant respiratory disorders other than IPF

          -  Active vasculopathy or use of vasoactive drugs

          -  Known HIV or chronic viral hepatitis

          -  Patients with active tuberculosis or latent tuberculosis infection

          -  Evidence of any clinically significant, severe or unstable, acute or chronically
             progressive medical (other than IPF) or surgical disorder, or any condition that may
             affect patient safety in the judgment of the investigator

          -  Clinically significant abnormal ECG at screening

          -  Clinically significant laboratory tests at screening

          -  Current history of substance and/or alcohol abuse

          -  Females who are lactating or who are pregnant.

          -  Use of any registered therapy targeted to treat IPF within 4 weeks prior to screening

          -  Use of any cytotoxic/immunosuppressive agent including but not limited to
             azathioprine, cyclophosphamide, methotrexate and cyclosporine within 4 weeks prior to
             screening

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840008</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840009</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840011</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840005</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840013</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840014</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840010</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124003</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124001</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124002</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152003</name>
      <address>
        <city>Santiago</city>
        <zip>750-0691</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152001</name>
      <address>
        <city>Santiago</city>
        <zip>7500710</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152002</name>
      <address>
        <city>Santiago</city>
        <zip>8380456</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484003</name>
      <address>
        <city>Mexico City</city>
        <zip>40766</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484002</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724001</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724002</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <disposition_first_submitted>January 22, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>January 22, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 15, 2016</disposition_first_posted>
  <last_update_submitted>January 22, 2016</last_update_submitted>
  <last_update_submitted_qc>January 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

